InMed Pharmaceuticals
9 hedge funds and large institutions have $14.5K invested in InMed Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 2 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
0.13% less ownership
Funds ownership: 0.15% → 0.02% (-0.13%)
18% less funds holding
Funds holding: 11 → 9 (-2)
87% less capital invested
Capital invested by funds: $109K → $14.5K (-$94.9K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$24 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$84K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$6.22K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$2.83K |
| 4 |
ASN
Advisory Services Network
Atlanta,
Georgia
|
-$6 |
| 5 |
TWA
TCI Wealth Advisors
Tucson,
Arizona
|
-$6 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $12.6K | -$6.22K | -257 | -27% |
|
|
2
Bank of America
Charlotte,
North Carolina
| $1.7K | +$24 | +1 | +1% |
|
|
TWC
3
TD Waterhouse Canada
Toronto,
Ontario, Canada
| $103 | – | – | – |
|
4
BlackRock
New York
| $46 | – | – | – |
|
5
Osaic Holdings
Scottsdale,
Arizona
| $35 | – | – | – |
|
|
AWM
6
AllSquare Wealth Management
Albany,
New York
| $26 | – | – | – |
|
|
FDCDDQ
7
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $18 | – | – | – |
|
8
National Bank of Canada
Montreal,
Quebec, Canada
| $11 | – | – | – |
|
|
9
Renaissance Technologies
New York
| – | -$84K | -3,875 | Closed |
|
|
10
UBS Group
Zurich,
Switzerland
| – | -$2.83K | -131 | Closed |
|
|
ASN
11
Advisory Services Network
Atlanta,
Georgia
| – | -$6 | – | – |
|
|
GCM
12
Gables Capital Management
Miami,
Florida
| – | -$1 | – | – |
|
|
TWA
13
TCI Wealth Advisors
Tucson,
Arizona
| – | -$6 | – | – |
|
INM Hedge Fund Activity: Q2 2023 in Review
9 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in InMed Pharmaceuticals (INM) for Q2 2023, worth a combined $14.5K — down 87% from $109K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of INM and 0 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 1 added.
The largest buyer was Bank of America, adding an estimated $24. The largest seller was Renaissance Technologies, exiting entirely with an estimated $84K sold.
- 9 institutional investors held InMed Pharmaceuticals (INM) as of Q2 2023, down from 11 in Q1 2023.
- Funds reported $14.5K of InMed Pharmaceuticals stock for Q2 2023, down 87% quarter-over-quarter.
- 0 funds opened new InMed Pharmaceuticals positions in Q2 2023 and 2 closed out, a net change of -2 holders.
- The largest InMed Pharmaceuticals buyer in Q2 2023 was Bank of America, an estimated $24 added.
- The largest InMed Pharmaceuticals seller in Q2 2023 was Renaissance Technologies, an estimated $84K sold.
Based on aggregated 13F filings for Q2 2023.